ReviewNature reviews. Urology2010
MRI for men undergoing active surveillance or with rising PSA and negative biopsies.
Review in Nature reviews. Urology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 24 citations in OpenAlex.
- Focal therapy for localized prostate cancer: is there a "middle ground" between active surveillance and definitive treatment?Asian journal of andrology · 2018Article
- Magnetic resonance imaging for prostate cancer: Comparative studies including radical prostatectomy specimens and template transperineal biopsy.Prostate international · 2015Review
- Current role of multiparametric magnetic resonance imaging in the management of prostate cancer.Korean journal of urology · 2015Review
- Transperineal biopsy of the prostate--is this the future?Nature reviews. Urology · 2013Review
- [Potential of PET/MRI for diagnosis of prostate cancer].Der Radiologe · 2013Article
- Performance characteristics of MR imaging in the evaluation of clinically low-risk prostate cancer: a prospective study.Radiology · 2012Article
- Active surveillance for low-risk prostate cancer: knowledge, acceptance and practice among urologists.Prostate cancer and prostatic diseases · 2012Article
- Active surveillance for prostate cancer: past, present and future.Current opinion in oncology · 2012Review
- Lupeol, a novel androgen receptor inhibitor: implications in prostate cancer therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Article
- Active surveillance for favorable-risk prostate cancer: a short review.Korean journal of urology · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The role of imaging in treatment decision-making for patients with prostate cancer is to characterize the cancer already diagnosed on biopsy, to determine tumor location, to assess tumor volume, and to exclude more-extensive disease. MRI is currently the most established imaging modality for this purpose, with the highest sensitivity and specificity for detection and staging of prostate tumors. The development and wider adoption of active surveillance and focal treatment approaches would also benefit from accurate localization of cancer. As such, 3 T MRI and multiparametric approaches are being developed as tools for the localization and staging of prostate cancer. Men wishing to commence or remain on active surveillance might benefit by having larger cancers identified before embarking on this management strategy. MRI might have its greatest role in patients where there is a discrepancy between PSA and biopsy results suggesting a potential missed prostate tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.